Invention Grant
- Patent Title: Humanized anti-CD73 antibodies
-
Application No.: US16060343Application Date: 2016-12-09
-
Publication No.: US10822426B2Publication Date: 2020-11-03
- Inventor: Emily Piccione Griffin , Richard A. Miller , Gerhard Johann Frey , Hwai Wen Chang
- Applicant: Corvus Pharmaceuticals, Inc. , BioAtla, LLC
- Applicant Address: US CA Burlingame US CA San Diego
- Assignee: CORVUS PHARMACEUTICALS, INC.,BIOATLA, LLC
- Current Assignee: CORVUS PHARMACEUTICALS, INC.,BIOATLA, LLC
- Current Assignee Address: US CA Burlingame US CA San Diego
- Agency: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
- International Application: PCT/US2016/065968 WO 20161209
- International Announcement: WO2017/100670 WO 20170615
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/395 ; G01N33/573 ; G01N33/84 ; A61P35/00
Abstract:
Provided herein are, inter alia, humanized 1E9 antibodies capable of binding CD73. The humanized antibodies are useful for the treatment of cancer. Further provided are nucleic acids encoding humanized 1E9 antibodies and methods of inhibiting cell proliferation using the humanized antibodies provided herein.
Public/Granted literature
- US20190077873A1 HUMANIZED ANTI-CD73 ANTIBODIES Public/Granted day:2019-03-14
Information query
